Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on October 24, 2025, by Pasithea Therapeutics Corp., a Delaware corporation trading on The Nasdaq Capital Market under the symbols KTTA (Common Stock) and KTTAW (Warrants). The filing addresses Item 5.02 regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. However, management explicitly cites "current cash constraints" as a primary driver for the compensation adjustments detailed in this report.
Material Changes and Compensation Adjustments
The Board of Directors approved significant changes to executive and director compensation, effective retroactively to January 1, 2025, or October 1, 2025, to align with peer groups while conserving cash.
- Executive Officer Cash Compensation:
- CEO Dr. Tiago Reis Marques: Base salary increased to $533,000; target bonus percentage decreased to 55% of base salary.
- CFO Daniel Schneiderman: Base salary increased to $391,000; target bonus percentage increased to 40% of base salary.
- Director Cash Compensation:
- Audit Committee Chair: Annual cash retainer increased by $5,000 to $15,000 (effective Jan 1, 2025).
- Chair of the Board: Total annual cash compensation reduced from $100,000 to $35,000 (effective Oct 1, 2025) to conserve cash.
- Consulting Arrangement:
- Prof. Lawrence Steinman's quarterly consulting fee was reduced from $25,000 to $1.00 (effective Oct 1, 2025).
Equity Awards and Vesting
The Board approved stock option awards with an exercise price of $0.715 per share (closing price on Oct 24, 2025) under the 2023 Stock Incentive Plan:
- Executive Officers: Dr. Marques (493,341 shares), Mr. Schneiderman (317,266 shares), and certain employees (aggregate 352,266 shares). Vesting: 33% after one year, remainder in quarterly installments over two years.
- Non-Employee Directors: Prof. Steinman, Dr. Leahy, Mr. Dumesnil, and Mr. Novak (42,913 shares each). Vesting: 100% after one year.
- Special Award: Prof. Steinman received a one-time award of 200,000 shares in recognition of cash conservation efforts. Vesting: 100% after one year.
- Change in Control: All awards fully vest upon a Change in Control.
Outlook, Risks, and Management Commentary
Management commentary emphasizes the necessity of cash conservation due to current financial constraints. The reduction in cash compensation for the Board Chair and the consulting agreement with Prof. Steinman are direct responses to these constraints. The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the context of the compensation restructuring.
Key Facts for Investor Verification
- Verify the company's current cash runway and liquidity position given the explicit mention of "cash constraints."
- Confirm the dilution impact of the newly granted options (aggregate of approximately 1.5 million shares) on existing shareholders.
- Review the 2023 Stock Incentive Plan terms to understand the full scope of the vesting schedules and Change in Control provisions.
- Assess the strategic rationale for increasing executive base salaries while simultaneously reducing director and consultant cash fees.